The assumption that CT colonography is the logical choice for pairing with optical colonoscopy to stage colorectal cancer took a hit at the RSNA meeting today. A prospective study from Europe shows that whole-body FDG-PET/CT is significantly more accurate than CT colonography for staging colorectal tumors.
The assumption that CT colonography is the logical choice for pairing with optical colonoscopy to stage colorectal cancer took a hit at the RSNA meeting today. A prospective study from Europe shows that whole-body FDG-PET/CT is significantly more accurate than CT colonography for staging colorectal tumors.
The study of 52 patients performed by Dr. Peter Veit at the University of Essen in Germany found that whole-body FDG-PET/CT colonography was 74% sensitive for T-staging, compared with a sensitivity rate for CT colonography of 52%. The results were confirmed by histopathology specimens and clinical follow-up 310 days after the initial evaluation. Veit has since joined the nuclear medicine residency program at the University of Zurich in Switzerland.
FDG-PET/CT colonography contributed to alteration of the clinical management of four patients, Veit said. In one instance, PET/CT colonography uncovered a second liver metastasis that was not detected with CT colonography alone. That finding identified the need for a second surgical session to resect the second lesion.
No significant differences in metastasis or lymph node staging were observed.
PET/CT colonography takes about seven minutes longer than the conventional 30-second PET/CT whole-body protocol for colorectal cancer staging, Veit said. Additional time is needed for pharmacological bowel relaxation and rectal water filling.
Study Reveals Benefits of Photon-Counting CT for Assessing Acute Pulmonary Embolism
April 23rd 2024In comparison to energy-integrating detector CT for the workup of suspected acute pulmonary embolism, the use of photon-counting detector CT reduced radiation dosing by 48 percent, according to newly published research.
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
AI Adjudication Bolsters Chest CT Assessment of Lung Adenocarcinoma
April 11th 2024The inclusion of simulated adjudication for resolving discordant nodule classifications in a deep learning model for assessing lung adenocarcinoma on chest CT resulted in a 12 percent increase in sensitivity rate.